Eudaimonia Advisors’s PetMed Express PETS Stock Holding History

Eudaimonia Advisors’s Portfolio PETS Stock Details PETS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-33,000	Closed	-$338K	–	147
2023 Q3	$338K	Hold	33,000	–	–	0.24%	112
2023 Q2	$455K	Hold	33,000	–	–	0.31%	89
2023 Q1	$536K	Buy	+33,000	New	+$621K	0.36%	83

Other funds holding PETS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eudaimonia Advisors's PETS Position: Q4 2023 in Review

Eudaimonia Advisors sold out of PetMed Express (PETS) in Q4 2023, closing a stake of 33,000 shares — an estimated $338K sold.

Eudaimonia Advisors first reported a position in PETS in Q1 2023 and held it in 3 quarters. The position peaked at $536K in Q1 2023. 130 funds tracked by Wall St. Rank hold PETS as of Q4 2023.

Eudaimonia Advisors reported no remaining PetMed Express position as of Q4 2023 after selling out during the quarter.
Eudaimonia Advisors sold 33,000 PetMed Express shares in Q4 2023, an estimated $338K.
Eudaimonia Advisors first reported a position in PetMed Express in Q1 2023 and held it in 3 quarters.
Eudaimonia Advisors's PetMed Express position peaked at $536K in Q1 2023.
130 funds tracked by Wall St. Rank held PetMed Express as of Q4 2023.

Based on Eudaimonia Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.